Episode 40

Osteoarthritis, funding and the reality of becoming a scientist

Published on: 26th October, 2026

Why do joints fail as we age, and why, after decades of research, is there still no drug that reliably stops osteoarthritis from progressing?

Daphna Stern speaks with Maria Kyriazi, a DPhil researcher at the University of Oxford studying ageing and osteoarthritis.

Still in her twenties, Maria gives us a view of science that we do not often hear. She talks openly about experiments that fail after months of work, almost having to give up her Oxford DPhil because she could not fund it, and the pressures young scientists face to produce and publish exciting results.

They also discuss why osteoarthritis is far more complicated than the old idea of “wear and tear”, what ageing changes inside our joints, why promising research has repeatedly failed to become effective treatments, and whether we might eventually be able to treat the disease itself rather than simply manage the pain.

About the guest

Maria Kyriazi is a DPhil student in Molecular and Cellular Medicine at the University of Oxford, where she researches the age-related mechanisms involved in osteoarthritis. Originally from Athens, she came to the UK to study Biomedical Genetics at Newcastle University before completing an MRes in Ageing and Health and moving into doctoral research at Oxford.

In October 2026, Maria received the Korenchevsky Prize for her research into ageing and osteoarthritis at the British Society for Research on Ageing annual scientific meeting. She previously won the Young Star Award at the Greek International Women Awards. She is a Mellon Longevity Graduate Scholar at Oriel College and an Onassis Foundation Scholar.

Her research examines how ageing processes, including autophagy and cellular senescence, change within the joint and may contribute to the development of osteoarthritis.

Maria Kyriazi — Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences

Alsaleh Group | Ageing in the musculoskeletal system and beyond earth — Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences

00:00 Why study ageing and osteoarthritis?

01:38 How did Maria get from Athens to Oxford?

06:32 Why study ageing itself?

09:59 What actually happens in osteoarthritis?

14:00 Is osteoarthritis caused by ageing or injury?

17:06 What happens when cellular recycling starts to fail?

19:40 Why have osteoarthritis treatments repeatedly failed?

22:12 What does scientific failure really look like?

30:32 Why is it so difficult to fund a scientific career?

39:30 Does funding pressure encourage scientists to oversell results?

41:57 How do young scientists protect research integrity?

44:52 Could we eventually treat osteoarthritis itself?

49:02 Rapid-fire questions

51:43 Closing reflections

Transcript
Speaker A:

Foreign.

Speaker B:

Welcome to Beyond Longevity, the podcast that explores not just how we age, but how we can build a longer, healthier future for ourselves.

Speaker B:

Why do some joints begin to fail as we age?

Speaker B:

And why, after decades of research, do we still have no drug that can reliably stop osteoarthritis from progressing?

Speaker B:

My guest today on Beyond Longevity is Maria Curiazi.

Speaker B:

She's in her 20s, originally from Athens, and is now doing her DPhil at the University of Oxford, where she researches aging and osteoarthritis.

Speaker B:

She originally thought she would become a doctor, but an early interest in genetics and aging pulled her towards research instead.

Speaker B:

What makes this conversation particularly interesting is that Maria is still near the beginning.

Speaker C:

Of her scientific career.

Speaker B:

She talks very openly about what that actually looks experiments failing after months of work, struggling to secure funding, the pressure to produce exciting results, and the reality that some talented young scientists may simply be forced out of academia due to financial struggle.

Speaker B:

We also look at osteoarthritis itself, why aging matters so much to the disease, and whether understanding what changes in an aging joint could eventually lead to treatments that do more than simply manage the pain.

Speaker C:

Hi, Maria, thank you so much for joining me on Beyond Longevity Today.

Speaker C:

You are in your 20s at Oxford University, doing your DPhil, which is Oxford's term for a PhD working on aging and osteoarthritis.

Speaker C:

But you grew up in Athens thinking your future might look very different.

Speaker C:

How did you get from Athens to Oxford?

Speaker A:

Thank you very much, Daphne.

Speaker A:

It's actually a very nice question to be asked.

Speaker A:

So coming to the UK was.

Speaker A:

It wasn't something that I really planned growing up.

Speaker A:

The plan was to stay in Greece essentially and study for a medical degree.

Speaker A:

Life brought it in a way that UK came as an opportunity and research came as an opportunity.

Speaker A:

And I had an offer to study biomedical genetics at Newcastle University.

Speaker A:

So I started the degree thinking that I would continue with graduate medicine afterwards.

Speaker A:

But I was really blessed with having amazing people to work with who showed me that how exciting research is and how great the field is.

Speaker A:

And that's also how I found out about aging research, because aging was the number one thing that came up in almost all of the diseases we were learning about, like how big of a role aging has in the development of these diseases.

Speaker A:

So eventually I decided that I wanted to delve deeper and do a master's degree.

Speaker A:

Right before that master's degree, I had the opportunity to meet Gada, who has played a huge role in my decision on doing a PhD afterwards.

Speaker A:

So I started working on this project in osteoarthritis with Gada, we got to know each other right after I submitted my undergraduate thesis, right after I finished bachelor's degree.

Speaker A:

And we've been working together ever since.

Speaker A:

I did a short project in between my bachelor's and my master's.

Speaker A:

And that was when I decided that maybe after my master's, I want to continue with a PhD.

Speaker A:

So one thing led to the other.

Speaker A:

I mean, I kept telling to myself, after this degree, I'll go back to Greece.

Speaker A:

But it's been eight years now and I'm still here.

Speaker A:

So I've been really, really lucky, I think, throughout this time.

Speaker A:

And I've worked with amazing people.

Speaker A:

And I'm really pleased by how life ended up being for me because I think it is early failure entering medical school.

Speaker A:

If circumstances were not like that, I would not have seen how amazing the research world is and how great it is to be working in research.

Speaker A:

So this is in a nutshell how I ended up here and how we also talk to each other today.

Speaker C:

So just to explain to the listeners, you were referring to Professor Agada Al Saleh, who's your research professor, and you do various different research projects with her, and she'll also be on Beyond Longevity soon.

Speaker C:

That's something to look forward to.

Speaker C:

Now, I think you have said that at one point, medicine seemed like the only career path if you wanted to improve people's health.

Speaker C:

What changed?

Speaker A:

Growing up, unfortunately, in Greece, research was not really something that we were taught about.

Speaker A:

So I knew that I wanted to work on something that has an impact in human health.

Speaker A:

And I wanted to work on something where I would be helping people in one way or the other with the main focus in health.

Speaker A:

So starting my bachelor's degree and learning more about research and all the amazing work that is done on the background, all the great work that is done on the behind the scenes, it sort of changed this idea that medicine is the only path by which we can sell people.

Speaker A:

And also speaking to researchers and learning more about all these wonderful work that people have been doing behind the scenes that unfortunately not many people know how much work and effort the researchers sometimes place to get the medicine out, to get the treatment out, to help people in the background.

Speaker A:

So getting to know more about this world, it was something that I think I saw myself in.

Speaker A:

And hence I decide to do this transition.

Speaker A:

And I say that knowing that in the very, very back of my head, I still have this like 0.1% of me saying, well, could we do a medical degree as well, but you never know how life brings it up.

Speaker A:

But now I'm really pleased with the fact that I am research, and I'm really pleased with the work I'm doing in the background.

Speaker C:

Anyway, you're so young, you know, there's lots of opportunities for you to.

Speaker C:

To try different areas, but.

Speaker C:

But you've touched upon it already.

Speaker C:

The fact that you kept seeing the same risk factor sort of coming up across different diseases, and they're all related to age, aging.

Speaker C:

Was that when you started thinking that aging itself might be the more interesting thing to study?

Speaker A:

Exactly, yeah.

Speaker A:

So it started.

Speaker A:

We were focusing a lot on genetic diseases and chronic diseases as well.

Speaker A:

And it kept popping up in a way, like in all the risk factors in a way.

Speaker A:

Advanced age seemed to be the common risk factor across almost all of these diseases.

Speaker A:

They wouldn't explain us why.

Speaker A:

We never delved deep into that.

Speaker A:

So I personally started becoming curious as to why.

Speaker A:

What changes we've aged, why older adults develop these diseases, what are the underlying mechanisms.

Speaker A:

And so it started as a personal search, and hence how I found out of the hallmarks of aging and all these changes, the molecular changes we see with age that we can label and say these are these, and we can use them to understand the diseases more in depth and better.

Speaker A:

And then at the final year of my degree, I knew that the research project that I wanted to do, I wanted to focus on something directly on aging.

Speaker A:

And I was really lucky to.

Speaker A:

To work with a professor called Professor Mary Herbert, who is working on the reproductive field in female reproductive aging.

Speaker A:

And I did a short project there where we were looking at why women after the age of 35 are prone to having children with down syndrome and other commotional abnormalities.

Speaker A:

And I think this was the turning point.

Speaker A:

After that research project, I was like, okay, I want to specialize in this field.

Speaker A:

I want to get to know more about this field.

Speaker A:

And so I was very pleased with the fact that Newcastle University had a degree, a master's degree in aging research.

Speaker A:

I applied to that degree.

Speaker A:

It was at that point where I met Professor Gadal Saleh as well.

Speaker A:

And I came here in Oxford for that short research project.

Speaker A:

And we decided that maybe it would be good if we put a research project down together.

Speaker A:

And I did part of my master's degree here in Oxford, Wiltshire, and part of my degree at Newcastle University, where I got my master's degree from.

Speaker A:

So it started as an early curiosity, which I didn't know how to execute and how to actually get into the field.

Speaker A:

I didn't even Know at the time that there was a whole research field that eventually, slowly, slowly developed to something that, to me personally, I think at this stage of time, we are the early career people that work in aging field.

Speaker A:

We are really lucky because I think the field is finally getting the recognition that it deserves.

Speaker A:

It finally gets the interest and the research focus that it deserves.

Speaker A:

And we are really lucky to enter the field, I think, in this stage.

Speaker C:

So all this eventually brought you to osteoarthritis.

Speaker C:

And before we get to talk about your research, I think we really need to establish exactly what we mean when we say osteoarthritis, because most of the listeners would have heard of osteoarthritis, of course, but without necessarily understanding what it actually is.

Speaker C:

So for somebody who has heard the word but doesn't really know what it is.

Speaker A:

So osteoarthritis is a disease of the joints, where the cartilage, which is the soft tissue that supports the joint, it's the main site of damage.

Speaker A:

So we have severe damage in the, what we call articular cartilage, that soft tissue that supports the joints, which is also the soft tissue that we know that with age we slowly lose it, it gets damaged, it gets degraded.

Speaker A:

And this is also why people with age become shorter, because we also have articular cartilage in our spine as well.

Speaker A:

So, yeah, it's the soft tissue that supports the joints.

Speaker A:

And in osteoarthritis we have severe damage in this soft tissue, but we also have some other changes in other sites.

Speaker A:

Let's say the synovial tissue, which is the structure that further supports the joints.

Speaker A:

And it's a really common joint disease.

Speaker A:

Unfortunately, we know that one in three adults, after the age of 65, develop osteoarthritis.

Speaker A:

You can have osteoarthritis in many, many tissues as well.

Speaker A:

You can have in the knees, we can have in the hips.

Speaker A:

So so far there are no disease modifying therapeutics.

Speaker A:

We know that people that have the disease, they can only get some treatments for the pain, surfing to help decrease the pain they feel.

Speaker A:

And if the disease gets very severe, the only solution is joint replacement.

Speaker A:

So our group is really interesting in finding ways as to how we can either prevent the disease, delay the disease, but also develop therapeutics to treat the disease and avoid taking the surgical route.

Speaker C:

So I just want to make sure that the listener really understands the distinction here.

Speaker C:

So at the moment, medicine can manage pain and symptoms and I guess maintain some function.

Speaker C:

And in severe cases you need surgery.

Speaker C:

But there is a lack Of a drug that reliably stops or even reverses the underlying disease process, correct?

Speaker A:

Yes, that's correct.

Speaker A:

So we are trying to understand, first of all, why are older adults prone to developing osteoarthritis?

Speaker A:

So what are the mechanisms, what changes in the cells and in the tissues?

Speaker A:

With a hope to find something that we can detect potentially there early on or at early stages of the disease, or before it accumulates to the very severe stage, and also develop something to potentially treat the disease itself.

Speaker A:

So sort of reverse it.

Speaker A:

But this is a little bit more challenging given that the cartilage is a tissue that we know doesn't rejuvenate.

Speaker A:

Though there is a lot of evidence lately that says that maybe it might be able to rejuvenate as well.

Speaker A:

But the research is still getting there.

Speaker A:

Um, there's still a lot work that is done to see and validate that.

Speaker A:

So we are also trying to see if we can ourselves, by understanding these underlying mechanisms, develop something that can reverse this damage.

Speaker A:

It can prevent but also reverse this.

Speaker A:

This damage.

Speaker A:

But yeah, so far, unfortunately, the.

Speaker A:

The only management is via painkillers, things to help with the pain.

Speaker C:

Is osteoarthritis something that happens because we get old, or is aging one factor that makes it more likely?

Speaker A:

This is a great point, and it's something that we focus on is the distinction between post traumatic osteoarthritis and age related osteoarthritis.

Speaker A:

So there are two points to make here.

Speaker A:

One is that damage.

Speaker A:

So if, let's say you have an injury, you are likely potentially to develop osteoarthritis.

Speaker A:

So this is something that also causes the disease.

Speaker A:

But the thing is that even if you have this early trauma, even if you have this early damage, let's say severe injury when you are young, most likely you'll develop the disease after the age of 65.

Speaker A:

So aging itself is, if not the greatest risk factor, one of the greatest risk factors for developing osteoarthritis.

Speaker A:

Other than that, obesity plays also a huge role in developing the disease.

Speaker A:

We think that by understanding aging itself and how aging impacts the the joints to ultimately develop osteoarthritis, we would hope to understand better about the disease itself and make this distinction between the aging role in the disease, but also how early trauma or trauma might make someone develop the disease and why they show the symptoms and develop the disease after 65.

Speaker C:

So I think most people that here osteoarthritis associated basically with wear and tear.

Speaker C:

What is wrong with that?

Speaker C:

Very limited explanation for Osteoarthritis.

Speaker A:

So this term as well, I know that people are trying to remove slowly from the field because it develops this sort of idea that the more you use your joints, the more likely it is to like have these injuries.

Speaker A:

It's not really 100% accurate.

Speaker A:

So we wouldn't describe it that much as a wear and tear disease anymore, but rather we would describe it as a disease that accumulates because of all these progressive damage that builds up as we get older and age and ultimately make the joints vulnerable.

Speaker A:

In a way, they create these diseases, this damage.

Speaker A:

But it doesn't mean that the more we exercise, the more we walk, the more likely it is to develop the disease.

Speaker A:

Of course not.

Speaker A:

There are some evidence that in intense exercise, like elite marathon athletes, that's run like intensely, there might be like some injuries in the joint or some this, we're in pair.

Speaker A:

But as a term, I think slowly, slowly we start to remove it from the osteoarthritis pill because it's not that much accurate and can create some sort of inaccuracies about the development of the disease.

Speaker C:

So one of the processes you're studying is autophagy.

Speaker C:

Autophagy, put very simply, is the cleaning out of dead cells.

Speaker C:

In simple terms, what is a healthy young cell doing that an older cell becomes less good at doing?

Speaker A:

So in terms of autophagy, as you said, it's the cell recycling process.

Speaker A:

So when we are young and they have any sort of damage or any sort of problems in the cells and the tissues, autophagy gets, activates and essentially eats up these damaged cells and recycles them and reuses them.

Speaker A:

So when we get older, and as we get older, we know that it doesn't work that well.

Speaker A:

So it's less acidic, efficient in activating this process and doing pericycline, activating pericycline pathway.

Speaker A:

But we also know that the proteins of autophagy, they get declined, they reduce with age.

Speaker A:

So ultimately this creates a buildup of protein aggregates or clumsies of proteins that cannot be cleared up with the body, in the body, and ultimately can lead to more damage in the tissue and more efficient, effective downstream pathways that get activated.

Speaker C:

So what actually happens if the recycling system starts to fail?

Speaker A:

Ultimately you would have a buildup of damaged molecules, damaged proteins, things that cannot get reused, they can't get cleaned up.

Speaker A:

And this can potentially lead to other problems downstream.

Speaker A:

So another mechanism I'm looking at is cellular senescence.

Speaker A:

It's the cell cycle arrest.

Speaker A:

The cells essentially stop dividing.

Speaker A:

So I'm trying to understand if autophagy is defective.

Speaker A:

If we have these problems on autophagy, does this lead to more cellular senescence as well as one of the mechanisms that we want to look at as a result of defective autophagy?

Speaker A:

Besides that, of course, there are other processes too.

Speaker A:

And we do know that autophagy plays a very big role in the tissues and the cells.

Speaker A:

So in the context of the joints, I am trying to understand, first of all, do we have effective autophagy in osteoarthritic joints and with age and more joints?

Speaker A:

And secondly, if we do have defective autophagy, if we have reduced autophagy, do we see any downstream problems that could lead to the disease development?

Speaker C:

We have plenty of promising research and promising mechanisms in osteoarthritis, but we still don't have a drug that reliably stops the disease progressing.

Speaker C:

Where does the translation keep breaking down?

Speaker A:

That's also a very great point.

Speaker A:

So the thing with osteoarthritis research is it's much osteoarthritis as a disease is much more complicated than what we thought it was.

Speaker A:

So for many years we thought it was just a disease of the articular cartilage, where we had damage in the cartilage.

Speaker A:

And the past 20 years the field changed when we found out that we also have low grade, very mild inflammation in the joint as well, which we started looking into and try to understand how this low grade inflammation impacts the joints, impacts the articular cartilage, what is its role in the disease?

Speaker A:

So I think the translation breaks down in the fact that there much more to the story than what we think.

Speaker A:

And I think in the years ahead we will find out so many new things that we didn't know about the disease, about different tissues and cell types playing a role, and get a better idea as to what goes wrong and in what order.

Speaker A:

Because we see the articular cartilage as the main site of disease damage, but it could be the end of, of the disease development, it could be the last stage of getting the disease.

Speaker A:

So in our team, we are trying to understand about the whole joint, what problems we see in the whole joint.

Speaker A:

So we are looking in the synovial tissue as well.

Speaker A:

We're seeing these cells that we see, this low grade mild inflammation.

Speaker A:

And we try to understand what is the role of photophagy and salar senescence in those as well.

Speaker A:

And other studies as well are looking at things like the meniscus, which is the part of the tissue that provides further support in the joints, things like the bone, how it communicates with the cartilage, what is the role of the bone in the joints.

Speaker A:

So I think in the years ahead, we'll have a lot more information about the biology of the disease, and hence we'll get a lot more information as to how to tackle the disease and treat the disease.

Speaker A:

Which is why I think up until now, all these clinical trials and those treatments that we try to get to the market might have paid.

Speaker C:

So when you describe research results, or, you know, not just you, but your colleagues, science can sound quite orderly.

Speaker C:

You have a question, you run the experiment, and then you discover something.

Speaker C:

But you have written about, and quite openly written about how different it feels when you are actually the person doing it.

Speaker C:

Tell us more.

Speaker A:

Research can be really magical, I think, to my opinion, because a lot questions come open up as you, as you try to solve a problem and try to give an answer to a problem, that it's really unexpected as well.

Speaker A:

So you may have a hypothesis, you may have an argument that based on all the previous research results, sounds the logical thing, the next step.

Speaker A:

And then you test it in the lab and it doesn't seem to be the case.

Speaker A:

And you have to, like, take a step back and try to understand why.

Speaker A:

So to me, when I initially started in the lab, I thought that it would be an analytic resort process that we have this question, we have this outcome we hope for.

Speaker A:

We want to test 1, 2, 3 things.

Speaker A:

So it's a straight line.

Speaker A:

We will get there in, let's say, two, three months.

Speaker A:

And then you start testing it out and you see that actually it may take two, three years.

Speaker A:

And for some people, it can take a whole career.

Speaker A:

And this is because, for one reason or another, things don't work out from the start.

Speaker A:

And more questions may open up, more problems may come along the way.

Speaker A:

And though it can be frustrating many times, especially if you're a PhD student trying to finish your PhD, it can also be very mesmerizing in a way, because it shows you how beautiful biology is and how much more complex nature is than what I think.

Speaker A:

But also retrospectively, when you see things at the end, you see how simple it is to.

Speaker A:

It's just the fact that you didn't see the results you hoped from, you didn't see the result that you hoped for since the start doesn't mean that it was actually that complex.

Speaker A:

Maybe the answer was right there all the way.

Speaker A:

It's just you didn't see, um, which is, it's adding up to how Beautiful biology and research is.

Speaker C:

You sound so positive and so easy about it.

Speaker C:

But I do know you once described being in a microscope room after 9 o' clock on a Friday night, after weeks and weeks and weeks of preparing samples and you realized that the experiment had failed yet again.

Speaker A:

It is true.

Speaker A:

It can be really challenging at times, especially if you hope to see a result.

Speaker A:

You hope to get these very well desired figure.

Speaker A:

You've been working on something for so long and the result phase after months of work.

Speaker A:

But I like to stay positive.

Speaker A:

I think eventually things work out and if they don't work out for a long time, eventually something even better than what you initially anticipated for is on its way.

Speaker A:

I think in terms of my PhD, I'm at that stage now.

Speaker A:

I've been working on something for so, so long, working be so many failures along the way and so many problems and barriers.

Speaker A:

But I'm quite optimistic that something really good, something like in terms of like the research results and putting together all the data that I have so far, something really good is on its way.

Speaker A:

Something very optimistic about like the, the biology that part of the research we are studying is on its way.

Speaker A:

Or at least I hope so.

Speaker C:

How do you know when an experiment needs another attempt, even though the result is actually telling you that your idea was wrong?

Speaker A:

This is a hard one.

Speaker A:

Sometimes you don't want to admit to yourself that the result is actually true, but the idea is wrong.

Speaker A:

So you might do two, three, four times, repeat the experiment just to convince yourself.

Speaker A:

But eventually, like after a few times, if you keep getting the same outcome regardless of the number of times you run it, it means that the hypothesis is wrong, not the experiment.

Speaker A:

There have been cases as well where we, we do have technical issues, hence why it's good to repeat.

Speaker A:

But if you constantly get the result and move on and try to explain why the hypothesis and the idea is wrong, and sometimes I think these results, these negative results, these data that show something different than what you expected, sometimes I think they can be the most interesting part of the biology because this is the stage where you're trying to understand why and you try to take a step back and think of biology, think of your research as a whole and try to see where your result fits in the bigger picture.

Speaker A:

So it can be frustrating, but it's certainly something that helps you formulate your hypothesis even better.

Speaker C:

And you've won many awards considering how young you are.

Speaker C:

And you're obviously so good at what you're doing because I think a former supervisor once suggested you must have copied your work because they did not believe it could be yours.

Speaker C:

And while that's a huge compliment, I'm sure down the line.

Speaker C:

But in that moment, what does something like that do to a young researcher's confidence?

Speaker A:

First of all, I mean, thank you so much.

Speaker A:

It's.

Speaker A:

It's really humbling.

Speaker A:

I'm really grateful to hear, like, all these nice words.

Speaker A:

And it's certainly really motivational and helpful in a way, I think, at least to me personally, these awards are just an indication that maybe we are on the right track.

Speaker A:

I am a person that likes to take a step back and think about the next step.

Speaker A:

So it's really nice to be recognized, especially at this stage.

Speaker A:

But also it's an indication that, okay, what's next?

Speaker A:

What do we do next?

Speaker A:

What's the next step?

Speaker A:

What's the next goal?

Speaker A:

It might be something that comes from boards.

Speaker A:

I used to compete in Taekwondo when I was really young, and it's the attitude we.

Speaker A:

I had since very young age.

Speaker A:

But, yeah, I like to focus on the ultimate goal, the end goal, the future, the next steps, and not stay in the moment and get as much as I can along the way.

Speaker A:

And this is not about the awards itself.

Speaker A:

It's more about the experiences and the people and whom you get to meet, whom you get to talk to.

Speaker A:

Because, yes, an award is nice, but the people and the experiences and everything you get along the way is eventually what stays with you.

Speaker A:

And I think all these small opportunities, all these awards, they were something good in the sense of the relationships I built up out of them and the people that they ended up meeting out of them.

Speaker A:

So, yeah, I think I'm.

Speaker A:

I'm quite very.

Speaker A:

At the early stage, things seem to go well, and I'm glad with how things are going.

Speaker A:

But there is a lot more work, I think, that needs to be done from my side to get up to the ladder and start building my future in research.

Speaker C:

You'll definitely get there.

Speaker C:

You're young and ambitious enough to have a great impact on that field.

Speaker C:

You mentioned to me before that if you had not received your scholarship, you would have not been able to do this PhD.

Speaker C:

Tell us about the situation.

Speaker C:

Because obviously it's not just you who is in that position.

Speaker C:

There are many, many other young students that face the same dilemma.

Speaker A:

After I finished my bachelor's degree and during my master's degree, I had applied for this PhD program, I really want to work with GADA.

Speaker A:

I really wanted to continue working on this project.

Speaker A:

I had put a lot of faith in this Specific work in this specific theme, in this specific project.

Speaker A:

So I really wanted to do my PhD here.

Speaker A:

ed an offer to start a PhD in:

Speaker A:

But unfortunately I didn't come with funding.

Speaker A:

So when I started my Master's degree I had already the offer for the PhD for next year.

Speaker A:

But that meant that for a year we had to find out how I can fund this PhD project, which is something that unfortunately is becoming more and more common in the UK.

Speaker A:

People are starting PhDs without any funding.

Speaker A:

This was something that I would not be able to do myself.

Speaker A:

I would not have the opportunity to do a self funded PhD.

Speaker A:

So for that year we tried to find any possible way to get funding to be able to start the PhD and not drop the offer, not do something else.

Speaker A:

And it was an intense year.

Speaker A:

We reached out to as many funding bodies, people, opportunities we could.

Speaker A:

And I say we because I was not alone on this journey.

Speaker A:

e funding to start the PhD in:

Speaker A:

And eventually at the stage where I thought that well, I'll have to decline the offer.

Speaker A:

Life brought it in this way when I got an email from Professor Lynn Cox, who is now my second supervisor, who wanted to meet up and discuss about the funding situation of my potentially future PhD.

Speaker A:

And we had something that was something like a short interview though didn't feel like a short interview at the time, where we went through the data, how we went through the plan and the project and ultimately led up to building this collaboration and starting my PhD under the Mellon Longevity Graduate Scholarship, which is a scholarship that started in Oriel College here at the University of Oxford by the very, very generous donation of Mr. Jim Mellon, who is an alumni of Horiel College.

Speaker A:

holarship and start my PhD in:

Speaker A:

And on top of that I had also applied to Dionysus foundation back in Greece for a short scholarship which I also felt that I wouldn't get at the time.

Speaker A:

And I was very fortunate and like enough to receive some small scholarships and funding from there too.

Speaker A:

So right in the moment when I thought that well, maybe I will not be able to start this PhD, I ended up having two very great opportunities, two great scholarships and truly I think I cannot praise it enough.

Speaker A:

I'm truly grateful to both Mr. Jean Mellon and Professor Lynn Cox and Professor Gada Al Saleh, but also the Hamasis foundation because without their support I would not be able to do this PhD and do this research and continue this project.

Speaker C:

I think that's a very important topic for our listeners to hear because people don't really think like that.

Speaker C:

You know, they think, oh, it's a PhD.

Speaker C:

There's lots of funding for researchers, for students, it's a wonderful life to do your PhD.

Speaker C:

That's why I wanted you to highlight actually how tricky it is to get funding.

Speaker C:

So do you think the system weeds out potentially excellent scientists partly because many students just don't survive the system?

Speaker A:

Yes, I think it has gotten a bit worse over the last few years.

Speaker A:

Not just with PhD programs, but with research funding in general.

Speaker A:

And I think especially in academia, it's something that researchers keep bringing up, that the funding is just decreasing and decreasing more and more.

Speaker A:

It's a bit heartbreaking in a way to see, especially when you're at the start of your research journey.

Speaker A:

And unfortunately, I mean, at least to my knowledge, I don't know how people are dealing with that.

Speaker A:

If there is anything that has been going on in order to solve this and start to like put the pieces back in puzzle in a way.

Speaker A:

So I think that unfortunately many people are not as lucky as I was and they had to drop authors because.

Speaker A:

Because they were unable to take on a PhD program with no funding.

Speaker A:

Unfortunately, people were not able to continue with a postdoc because of the lack of funding, so they had to drop the project.

Speaker A:

Unfortunately, labs may close or are closing because of lack of funding.

Speaker A:

And it's something that I think needs to be addressed more in a way and try to find ways to sort it out, try to find ways to fund research because there is great research that is going on, there is some great ideas that need to be tested.

Speaker A:

There is a huge gap in the field that needs to be filled.

Speaker A:

And there are certainly the motivation and the enthusiasm and the.

Speaker A:

A lot of hardworking scientists that want to do this research, they want to do these experiments, they want to tackle this questions with answers.

Speaker A:

So funding is a huge problem I think right now that needs to be addressed and we need to find ways to help bring more funds, not just imaging research, but in other fields as well.

Speaker A:

And something that especially I think for my side as an early career, we also need to put our coin into the table and ourselves also get involved on helping get more funding.

Speaker A:

Because at the end of the day, the next generation is the future.

Speaker A:

So if there is this problem, if like lead senior researchers are struggling with that, eventually we will struggle with that and we start, we have already started to struggle with that.

Speaker A:

So we need from our side Also to find ways to help with that, to apply to opportunities, but also to have the opportunities to apply to from the first place.

Speaker A:

Um, so, yes, funding is something that I get quite passionate about because I know how much issues researchers have over the last few years with getting funding to do the research.

Speaker C:

And the funding problem does not just end once you have your PhD, right.

Speaker C:

So what actually happens to somebody in, in your position next?

Speaker C:

And also, do you see good young scientists leaving research because they simply cannot make that uncertainty work financially viable?

Speaker A:

Yes, definitely, certainly.

Speaker A:

And sometimes it feels like the system is pushing you out not because you are not good enough, not because you are not enthusiastic or motivational enough, not because your research is not good enough, but because the competition has increased so much and the funding seems to be less and less.

Speaker A:

So it seems to be like it's getting harder and harder.

Speaker A:

So I think especially nowadays there are a lot of people that decide to take a step back and be research, academic research, and try to think of alternative potential careers.

Speaker A:

Exactly because of this lack of funding.

Speaker A:

Exactly because of this issue.

Speaker A:

So it is something that I think concerns us a lot and something that we do have in the back of our head, especially with how things are changing over the last few years.

Speaker A:

But I would like to stay optimistic and say that I hope that in the coming years, and given that we all acknowledge that this is an issue, we'll start to tackle it and eventually solve it.

Speaker C:

You've also written that these financial pressures can lead scientists to sometimes exaggerate or maybe slightly misinterpret results.

Speaker C:

And that's quite a serious criticism.

Speaker C:

What exactly do you mean by that?

Speaker C:

And you know, where's the line between presenting your work in the strongest possible way and overselling what the evidence actually shows?

Speaker A:

Yeah, this is also something that I've personally noticed, in a way, or I think we do see a lot, is it is a vicious cycle of funding and publishing and what journals ask and what is expected by a researcher.

Speaker A:

So we do see a lot that journals like these like groundbreaking research results, which are indeed great.

Speaker A:

But if it was that easy to get a cure for cancer, we would have gotten the cure for cancer already.

Speaker A:

So getting out the negative data, getting out the things that didn't work, are also really, really important in terms of advancing the research and the next step and the next research experiment.

Speaker A:

I think nowadays the expectations have increased a lot.

Speaker A:

And in order to get your idea funded or in order to get your paper out, sometimes people need to exaggerate in how they sell this idea or it is expected by them to, to exaggerate, to to get something groundbreaking.

Speaker A:

If you are actually in research and know how it works, it's not always the case if you don't see this groundbreaking result, but you do see something that will help to lead to this groundbreaking result retrospectively, eventually.

Speaker A:

It's important to address it honestly and say that yes, it's up, it's not yet, but it's close to the cure, and address it honestly.

Speaker A:

So it's a really tricky one to talk about, I think, and to try to explain.

Speaker A:

But I think the problem starts from the system and not from the researcher, that it makes the researcher eventually exaggerate or try hard to get these groundbreaking result that might not be there yet.

Speaker C:

So you now mentor younger researchers yourself.

Speaker C:

Are you seeing them come up against the same problems that you had to navigate?

Speaker C:

Is it getting better?

Speaker C:

Is it Getting worse?

Speaker A:

Amongst PhD students and amongst like younger people that started getting to the field at the start, you don't really realize because we see everything so romantic, size and you think that everything is just working perfect and you see your PIs as the goal that just everything is sorted out for them.

Speaker A:

And then as you enter deeper and deeper, slowly, slowly inside the field and the research and you see the problems that they are facing, you see the problems with the system, you see all these small issues, you slowly start to realize that it's not as perfect as you thought it was and that for them as well, for the senior people, is not as perfect as we think it is.

Speaker A:

So I think we see that there is an issue that needs to be tackled and we acknowledge it and we recognize it.

Speaker A:

The question is, how do we address it?

Speaker A:

Because this is something that I think as younger researchers, we don't really know.

Speaker A:

How do we address it?

Speaker A:

What do we do?

Speaker A:

We want to learn from the older ones.

Speaker A:

That's why I think it's really important to talking, to talk to these senior researchers and learn from their experiences.

Speaker A:

But yeah, we'll see.

Speaker A:

I don't know how the future will be.

Speaker A:

I don't know how the funding situation will be.

Speaker A:

I don't know how we will tackle it as young researchers.

Speaker A:

But I think having what we call research integrity, which is also one of the questions that I got asked, get into this PhD program going with strong research integrity eventually will get us there.

Speaker C:

What advice do you have for the young researchers you mentor who are interested into getting areas of longevity research?

Speaker A:

Speak to people, certainly get to know people and don't lose the enthusiasm.

Speaker A:

It can get tough.

Speaker A:

Many of the times.

Speaker A:

And I think the number one lesson that research is is that you have constant failures along the way, but eventually they build you up and any failure that comes in the way ends up being a lesson.

Speaker A:

And it makes you stronger and it makes you more ready for the next obstacle, for the next barrier, for the next problem.

Speaker A:

One thing that I wish I knew earlier on is that all these struggles, they are common.

Speaker A:

We see someone publishing a paper with some amazing results and we think that, oh, it worked out perfectly for them.

Speaker A:

Most of the cases it didn't, they also struggled, they had problems.

Speaker A:

So talking about them openly, I think helps a lot and also motivates you further to keep going.

Speaker C:

Very sound advice.

Speaker C:

Now you've started out wanting to improve human health.

Speaker B:

Do you found aging research.

Speaker C:

You managed to finally fund your PhD, and now your work is really starting to get traction and receive well deserved recognition.

Speaker C:

But you've also seen experiments fail and all the negative sides of it.

Speaker C:

You know, the financial uncertainty and you know, you have been rightfully quite critical of the scientific system.

Speaker C:

Knowing all that, do you still want to spend your life doing this?

Speaker A:

Yes.

Speaker A:

I don't know where the future will take me.

Speaker A:

I don't know if I'll end up staying in academia or transition to industry or do something completely different.

Speaker A:

But I know that I want to stay in the medical field.

Speaker A:

I know that I want to stay in aging research one way or another.

Speaker A:

I know that I want to be part of this.

Speaker A:

Because even if we have all these problems, even if there are all these issues, I really believe in this.

Speaker A:

God.

Speaker A:

I really believe that by putting your little stone, you can eventually help and lead to something good.

Speaker A:

And at the end of the day, what personally motivated me to enter this field and to enter medical research was doing something to help people.

Speaker A:

It was never about the finances, the money.

Speaker A:

It was never about the nation, the fame.

Speaker A:

It was doing something to give back to humanity.

Speaker A:

Which also sounds a bit romantic sidetracking.

Speaker A:

But for me, that was always my motivation.

Speaker A:

Hence why I want to become a doctor in the first place.

Speaker A:

So I really want to stay in this world.

Speaker A:

I really want to see the future of research.

Speaker A:

I really want to see all these problems that we face now to starting to.

Speaker A:

To slow down and get resolved slowly.

Speaker A:

I'm sure that many more will pop up in the future that we cannot even think about today.

Speaker A:

But I really want to stay in research and see the becoming better and better as the time progresses.

Speaker C:

So going back to osteoarthritis and the research you're doing there what is your immediate hope for that research and also what your hope long term the impact will be on helping the sufferers of osteoarthritis.

Speaker A:

So the research I am running so far, the question I have and the way I am trying to tackle down, I am hoping that we will be able to find something to understand the biology better, but also to therapeutically start to find answers to the questions we have.

Speaker A:

So we already have target that we are looking into and we already have a therapeutic that we want to test which is something that I'm currently working on and will be hopefully the final experiment of my PhD which ultimately we would hope that would go into clinical trials and then the lab and the future work will take over.

Speaker A:

In terms of osteoarthritis in general, I know that there is a lot of work that is done in getting clinical trials, getting treatments to be tested, especially here at Oxford.

Speaker A:

I know that there are a lot of people working on the clinical research side, the clinical trial side.

Speaker A:

So what I would hope for is that by the next 10 years at least we have something to help in the disease symptoms as well, besides the pain, finding the cure.

Speaker A:

I know this might be quite hard to do and I don't know if at least whilst I am alive if we'll be able to get there.

Speaker A:

But I would hope that at least we find something to start slowly treating the disease itself too, besides the pain.

Speaker A:

That's great.

Speaker C:

We're ending on a positive note.

Speaker C:

I always like that.

Speaker C:

But before I let you go, I'm going to ask you five rapid fire questions that I ask all my guests.

Speaker C:

So what's the single best piece of advice you would give your younger self?

Speaker A:

If you fail now, it's for a reason.

Speaker A:

Something better is on its way.

Speaker C:

Name one habit everyone should adopt for a longer, healthier life.

Speaker A:

I think that you just sleep well and eat well.

Speaker C:

And if you weren't in longevity science or what career would you have chosen?

Speaker A:

I think I would have become a doctor and I would have worked in the clinic.

Speaker C:

What micro dose habits like five minute routine or small daily action yields outsized longevity benefits.

Speaker A:

I would say taking short walks, walking and just enjoying nature.

Speaker A:

This is also something I think it's quite important, enjoying nature, walking and seeing the world can be really beautiful.

Speaker A:

Definitely.

Speaker C:

Effy, what's the craziest longevity myth you've encountered and is there any truth to it?

Speaker A:

I would say the crazy diets that people are trying, at least to me some of these sound extreme and I don't know.

Speaker A:

I think Especially the diet part is very personalized.

Speaker A:

So I would say crazy diet.

Speaker A:

Yeah, fair enough.

Speaker C:

And you don't think there's any truth to it?

Speaker A:

I don't know.

Speaker A:

I don't know.

Speaker A:

Some of them, I find them very extreme.

Speaker A:

I don't know.

Speaker C:

They know exactly what you mean.

Speaker A:

I mean, being Greek myself, the Mediterranean diet, I think is the best.

Speaker A:

Having olive oil and vegetables in your food and just like having nice meals with a lot of vegetables and nutrition in, I think this helps a lot.

Speaker A:

But I know some people go into some crazy diets that sound a bit extreme.

Speaker A:

And yeah, you may see some results.

Speaker A:

But no, I think you're right.

Speaker A:

Great answer.

Speaker C:

Well, listen, Maria, thank you so much for joining me today on Beyond Longevity.

Speaker C:

It was such an interesting conversation.

Speaker C:

And, you know, we have a lot of older researchers on or people who've been in the field a long time.

Speaker C:

So it was really interesting to cover that research angle from the view of a young researcher with all the struggles that it involves financially and trying to see where you go and what to do and find mentors.

Speaker C:

So thank you so much for sharing that side of the research.

Speaker A:

Thank you, Darkna, for inviting me and having this really, really nice discussion.

Speaker A:

Discussion.

Speaker B:

Maria gives us a side of science that we rarely see once the finished research appears.

Speaker B:

Behind a result can be months or years of experiments that fail.

Speaker B:

Behind a promising young scientist can be a funding system that determines whether they're able to continue at all.

Speaker B:

And behind some of the bold claims we read about scientific brain breakthroughs is a much messier reality for osteoarthritis.

Speaker B:

We still do not have a treatment that reliably stops or reverses the disease itself.

Speaker B:

Maria hopes her work can help move us closer to that.

Speaker B:

She's still at the beginning of her career, which is exactly where this perspective matters.

Speaker B:

We often hear from scientists once they are established.

Speaker C:

It is much rarer to hear what.

Speaker B:

It takes to become one.

Speaker B:

Thank you for joining me today on Beyond Longevity.

Speaker C:

Please rate, review and subscribe.

Next Episode All Episodes Previous Episode
Show artwork for Beyond Longevity

About the Podcast

Beyond Longevity
Decoding the future of ageing one conversation at a time
Beyond Longevity explores the science, medicine, technology, business and policy shaping longer, healthier lives. Host Daphna Stern speaks with leading researchers, clinicians, founders and experts about ageing biology, healthspan, preventive medicine, longevity biomarkers, AI in healthcare, nutrition, women’s health and the societal impact of longer lives. Each episode examines the evidence, separates credible science from hype and translates complex research into clear, practical conversations.

About your host

Profile picture for Daphna Stern

Daphna Stern

Born in Germany, but predominantly raised and educated in Oxfordshire and London.

Studied Law in London and also earned a Diploma in Clinical Nutrition and Health, reflecting a long-standing curiosity about how the body works.

Developed a lifelong fascination with health, wellbeing and optimisation of body and mind, which naturally evolved into a deep interest in longevity science.

Lived internationally, Monaco, the United States, Hong Kong, and Germany, before returning to London almost 15 years ago, gaining a broad global perspective on health, lifestyle, and ageing.
Mother of two, which further shaped a practical and long-term perspective on health, resilience, and wellbeing.

Not a scientist by training, but over the years has become deeply immersed in the longevity world through constant reading, learning, and questioning.

Well connected within the field, with a strong network of researchers, scientists, clinicians, investors, and innovators who are shaping the future of longevity.
Passionate about blending science, real human stories, and emerging ideas, and about translating complex research into clear, engaging conversations.

Founded Beyond Longevity to explore the future of health, ageing, and longer living, offering listeners cutting-edge research, meaningful insights, and actionable takeaways.
Driven by a belief that longevity is not just about living longer, but living better, and that understanding the science empowers people to make informed choices about their health.

linkedin.com/in/daphna-stern-4b203b398